These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 35195309)

  • 1. New 1,3,4-oxadiazoles linked with the 1,2,3-triazole moiety as antiproliferative agents targeting the EGFR tyrosine kinase.
    Mahmoud MA; Mohammed AF; Salem OIA; Gomaa HAM; Youssif BGM
    Arch Pharm (Weinheim); 2022 Jun; 355(6):e2200009. PubMed ID: 35195309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiproliferative activity, enzymatic inhibition and apoptosis-promoting effects of benzoxazole-based hybrids on human breast cancer cells.
    Omar AME; AboulWafa OM; Amr ME; El-Shoukrofy MS
    Bioorg Chem; 2021 Apr; 109():104752. PubMed ID: 33657444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and apoptotic antiproliferative action of new 1,2,3-triazole/1,2,4-oxadiazole hybrids as dual EGFR/VEGFR-2 inhibitors.
    Mahmoud MA; Mohammed AF; Salem OIA; Almutairi TM; Bräse S; Youssif BGM
    J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2305856. PubMed ID: 38326989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and modelling study of new 1,2,3-triazole/chalcone hybrids with antiproliferative action as epidermal growth factor receptor inhibitors.
    Maghraby MT; Salem OIA; Youssif BGM; Sheha MM
    Chem Biol Drug Des; 2023 Mar; 101(3):749-759. PubMed ID: 36366966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New 1,3,4-oxadiazole-chalcone/benzimidazole hybrids as potent antiproliferative agents.
    Hagar FF; Abbas SH; Abdelhamid D; Gomaa HAM; Youssif BGM; Abdel-Aziz M
    Arch Pharm (Weinheim); 2023 Feb; 356(2):e2200357. PubMed ID: 36351754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of new cyanopyridine/chalcone hybrids as dual inhibitors of EGFR/BRAF
    Abou-Zied HA; Beshr EAM; Gomaa HAM; Mostafa YA; Youssif BGM; Hayallah AM; Abdel-Aziz M
    Arch Pharm (Weinheim); 2023 Apr; 356(4):e2200464. PubMed ID: 36526595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights.
    Al-Warhi T; El Kerdawy AM; Said MA; Albohy A; Elsayed ZM; Aljaeed N; Elkaeed EB; Eldehna WM; Abdel-Aziz HA; Abdelmoaz MA
    Drug Des Devel Ther; 2022; 16():1457-1471. PubMed ID: 35607598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel 5-bromoindole-2-carboxylic Acid Derivatives as EGFR Inhibitors: Synthesis, Docking Study, and Structure Activity Relationship.
    Hassan OM; Kubba A; Tahtamouni LH
    Anticancer Agents Med Chem; 2023; 23(11):1336-1348. PubMed ID: 36847231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
    Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
    Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, apoptotic, and antiproliferative effects of 5-chloro-3- (2-methoxyvinyl)-indole-2-carboxamides and pyrido[3,4-b]indol-1-ones as potent EGFR
    Al-Wahaibi LH; Mohammed AF; Abdel Rahman FES; Abdelrahman MH; Gu X; Trembleau L; Youssif BGM
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2218602. PubMed ID: 37254958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of novel quinazolinone-based derivatives as EGFR inhibitors with antitumor activity.
    Sonousi A; Hassan RA; Osman EO; Abdou AM; Emam SH
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2644-2659. PubMed ID: 36146940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel scaffold hopping of potent benzothiazole and isatin analogues linked to 1,2,3-triazole fragment that mimic quinazoline epidermal growth factor receptor inhibitors: Synthesis, antitumor and mechanistic analyses.
    Rezki N; Almehmadi MA; Ihmaid S; Shehata AM; Omar AM; Ahmed HEA; Aouad MR
    Bioorg Chem; 2020 Oct; 103():104133. PubMed ID: 32745759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of novel heptamethine cyanine dye-erlotinib conjugates as antitumor agents.
    Yang X; Hou Z; Wang D; Mou Y; Guo C
    Bioorg Med Chem Lett; 2020 Dec; 30(23):127557. PubMed ID: 32949719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel 1,3,4-oxadiazole derivatives of naproxen targeting EGFR: Synthesis, molecular docking studies, and cytotoxic evaluation.
    Alsaad HN; Al-Jasani BM; Mahmood AAR; Tahtamouni LH; Saleh KM; AlSakhen MF; Kanaan SI; Yasin SR
    Drug Dev Res; 2024 Aug; 85(5):e22231. PubMed ID: 38956926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors.
    Srour AM; Ahmed NS; Abd El-Karim SS; Anwar MM; El-Hallouty SM
    Bioorg Med Chem; 2020 Sep; 28(18):115657. PubMed ID: 32828424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell Cycle Arrest and Apoptosis-Inducing Ability of Benzimidazole Derivatives: Design, Synthesis, Docking, and Biological Evaluation.
    Nazreen S; Almalki ASA; Elbehairi SEI; Shati AA; Alfaifi MY; Elhenawy AA; Alsenani NI; Alfarsi A; Alhadhrami A; Alqurashi EA; Alam MM
    Molecules; 2022 Oct; 27(20):. PubMed ID: 36296495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Pyrazoloquinolin-2-ones: Design, synthesis, docking studies, and biological evaluation as antiproliferative EGFR-TK inhibitors.
    Elbastawesy MAI; Aly AA; Ramadan M; Elshaier YAMM; Youssif BGM; Brown AB; El-Din A Abuo-Rahma G
    Bioorg Chem; 2019 Sep; 90():103045. PubMed ID: 31212178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of novel quinoline/chalcone/1,2,4-triazole hybrids as potent antiproliferative agent targeting EGFR and BRAF
    Mohassab AM; Hassan HA; Abdelhamid D; Gouda AM; Youssif BGM; Tateishi H; Fujita M; Otsuka M; Abdel-Aziz M
    Bioorg Chem; 2021 Jan; 106():104510. PubMed ID: 33279248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as antiproliferative EGFR and BRAF
    Al-Wahaibi LH; Gouda AM; Abou-Ghadir OF; Salem OIA; Ali AT; Farghaly HS; Abdelrahman MH; Trembleau L; Abdu-Allah HHM; Youssif BGM
    Bioorg Chem; 2020 Nov; 104():104260. PubMed ID: 32920363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New benzothienopyrimidine derivatives as dual EGFR/ARO inhibitors: Design, synthesis, and their cytotoxic effect on MCF-7 breast cancer cell line.
    Sobh EA; Khalil NA; Faggal SI; Hassan MSA
    Drug Dev Res; 2022 Aug; 83(5):1075-1096. PubMed ID: 35286757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.